As of the latest Form 4 filed Jul 6, 2026.
What Alkermes Plc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 51 most recent filings for ALKS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | 2026-07-06 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | SSale | −2.03K | $54.03 | $110K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SSale | −700.00 | $52.13 | $36.5K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | SSale | −8.30K | $51.46 | $427K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | MExercise | +5.00K | $19.34 | $96.7K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-12 | Wright Christopher I Director | SSale | −2.00K | $45.10 | $90.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-04 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | SSale | −2.03K | $43.05 | $87.6K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SSale | −9.00K | $41.67 | $375K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | MExercise | +5.00K | $19.34 | $96.7K | Yes (planned) | Form 4 ↗ |
| 2026-05-29 | 2026-05-29 | Parisi Samuel Joseph VP, Finance (Interim PAO) | SSale | −16.2K | $42.36 | $687K | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-29 | Parisi Samuel Joseph, VP, Finance (Interim PAO) | MExercise | +12.8K | $19.34 | $248K | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-29 | Parisi Samuel Joseph, VP, Finance (Interim PAO) | MExercise | +3.39K | $20.03 | $67.9K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Wright Christopher I Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Wright Christopher I, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Wilson Frank Anders Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Wilson Frank Anders, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | snyderman nancy lynn MD Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | snyderman nancy lynn MD, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | MCKEON BRIAN P Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | MCKEON BRIAN P, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Lurker Nancy Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Lurker Nancy, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | LAURENCIN CATO T Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | LAURENCIN CATO T, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | GAYNOR RICHARD Director | FTax | −1.48K | $36.95 | $54.5K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | GAYNOR RICHARD, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Cooke Shane Director | FTax | −3.21K | $36.95 | $118K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | Cooke Shane, Director | MExercise | +6.14K | — | — | No | Form 4 ↗ |
| 2026-05-04 | 2026-05-04 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | SSale | −2.03K | $33.20 | $67.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SSale | −9.00K | $33.40 | $301K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | MExercise | +5.00K | $19.34 | $96.7K | Yes (planned) | Form 4 ↗ |
| 2026-04-13 | 2026-04-11 | Lurker Nancy Director | FTax | −901.00 | $33.36 | $30.1K | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-11 | Lurker Nancy, Director | MExercise | +3.75K | — | — | No | Form 4 ↗ |
| 2026-04-06 | 2026-04-06 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | SSale | −2.03K | $34.57 | $70.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-04-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SSale | −9.00K | $35.51 | $320K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-04-01 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | MExercise | +5.00K | $19.34 | $96.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | SSale | −2.03K | $29.76 | $60.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Parisi Samuel Joseph VP, Finance (Interim PAO) | SSale | −6.89K | $29.29 | $202K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Nichols Christian Todd SVP, Chief Commercial Officer | SSale | −6.00K | $30.00 | $180K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SSale | −9.00K | $29.72 | $267K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | MExercise | +5.00K | $19.34 | $96.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | SSale | −2.03K | $29.29 | $59.6K | Yes (planned) | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Parisi Samuel Joseph VP, Finance (Interim PAO) | FTax | −808.00 | $30.73 | $24.8K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Parisi Samuel Joseph, VP, Finance (Interim PAO) | MExercise | +2.75K | — | — | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Nichols Christian Todd SVP, Chief Commercial Officer | FTax | −2.40K | $30.73 | $73.8K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Nichols Christian Todd, SVP, Chief Commercial Officer | MExercise | +5.41K | — | — | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Jackson Blair Curtis EVP, Chief Operating Officer | FTax | −3.69K | $30.73 | $114K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Jackson Blair Curtis, EVP, Chief Operating Officer | MExercise | +8.32K | — | — | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | FTax | −3.05K | $30.73 | $93.7K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Hopkinson Craig C., EVP R&D, Chief Medical Officer | MExercise | +6.87K | — | — | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | FTax | −3.05K | $30.73 | $93.7K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-26 | Gaffin David Joseph, EVP, CLO, Alkermes, Inc. | MExercise | +6.87K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ALKS’s full analysis or the market-wide insider trading feed. The tabs above jump to ALKS’s other SEC data.
Source: SEC Form 4 filings for ALKS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.